Analysts Set Phreesia, Inc. (NYSE:PHR) Price Target at $16.65

Phreesia, Inc. (NYSE:PHR) has been assigned a consensus rating of “Hold” from the nineteen brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.6471.

PHR has been the subject of a number of recent analyst reports. KeyCorp decreased their price objective on Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Mizuho decreased their price objective on Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Wall Street Zen raised Phreesia from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. Canaccord Genuity Group decreased their price objective on Phreesia from $22.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, May 28th. Finally, Citizens Jmp reaffirmed a “market perform” rating on shares of Phreesia in a research note on Wednesday, April 1st.

Insider Transactions at Phreesia

In other Phreesia news, insider David Linetsky sold 8,332 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $8.07, for a total transaction of $67,239.24. Following the completion of the transaction, the insider directly owned 224,056 shares of the company’s stock, valued at approximately $1,808,131.92. This trade represents a 3.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Yvonne Hui sold 10,063 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $9.08, for a total transaction of $91,372.04. Following the completion of the sale, the insider directly owned 25,991 shares of the company’s stock, valued at $235,998.28. The trade was a 27.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 50,493 shares of company stock valued at $461,983. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its stake in Phreesia by 2,395,000.0% during the first quarter. NewEdge Advisors LLC now owns 23,951 shares of the company’s stock valued at $201,000 after purchasing an additional 23,950 shares during the last quarter. Essential Partners LLC lifted its position in shares of Phreesia by 2,016.6% during the 1st quarter. Essential Partners LLC now owns 9,313 shares of the company’s stock valued at $78,000 after acquiring an additional 8,873 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Phreesia by 142.6% during the 1st quarter. Bank of America Corp DE now owns 1,001,057 shares of the company’s stock valued at $8,389,000 after acquiring an additional 588,444 shares during the last quarter. Amundi acquired a new stake in shares of Phreesia during the 1st quarter valued at $401,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Phreesia by 1,119.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company’s stock valued at $27,000 after acquiring an additional 3,001 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Stock Performance

Shares of PHR stock opened at $9.70 on Friday. Phreesia has a 12-month low of $7.77 and a 12-month high of $32.76. The firm has a market capitalization of $599.39 million, a price-to-earnings ratio of 64.65 and a beta of 0.91. The business has a 50 day simple moving average of $9.34 and a 200 day simple moving average of $13.16. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.76 and a quick ratio of 1.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Wednesday, May 27th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Phreesia had a return on equity of 5.13% and a net margin of 1.85%.The business had revenue of $130.94 million during the quarter, compared to analyst estimates of $130.08 million. During the same period in the prior year, the company posted ($0.07) EPS. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, equities research analysts anticipate that Phreesia will post 0.33 EPS for the current year.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Phreesia, increasing litigation and reputational risk for the company. PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit
• Negative Sentiment: The lawsuits focus on alleged misleading disclosures and may create uncertainty around Phreesia’s financial outlook and management credibility. Phreesia, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – PHR

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.